Davide Bedognetti

Director Tumor Biology, Immunology and Therapy Section

Sidra Medical and Research Center, Qatar



Dr. Bedognetti is the Director of the Immunology and Therapy Section at Sidra Medical and Research Center. Dr. Bedognetti received his MD and PhD in Clinical and Experimental Oncology and Hematology from the University of Genoa, Italy. After completing his medical residency in Medical Oncology in 2008, he joined the Infectious Disease and Immunogenetics Section (IDIS) of the US National Institutes of Health (NIH) where he completed his post-doctoral fellowship. Since 2013, he served also the Director of the Federation of Clinical Immunology Societies (FOCIS) Center of Excellence at NIH Clinical Center. He joined Sidra Medical and Research Center in 2014 as Director of the Tumor Biology, Immunology, and Therapy Section. Dr. Bedognetti is also Adjunct Associate Professor at the Hamad Bin Khalifa University in Doha. He received several awards including the SITC Travel Award, the Merit and Young Investigator Awards of the Conquer Cancer Foundation of ASCO, and the ASH Travel Award. Dr. Bedognetti is an active member of the Society for Immunotherapy of Cancer (SITC), American Society of Clinical Oncology (ASCO), Federation of Clinical Immunology Societies (FOCIS) and TCGA Pan-Immune working group. He currently serves as Editor of the Tumor Microenvironment Section for the Journal of Translational Medicine and as Editorial Board Member of Biomarkers Research. He has published 45 peer-reviewed scientific articles. Dr. Bedognetti and his team emphasize on identifying molecular mechanisms of immune-resistance and immune-sensitivity in breast cancer, the most prevalent cancer in women of the MENA region. The ultimate goal is to develop novel immunotherapeutic approaches that can improve the prognosis of women affected by this condition. The team employs high-throughput approaches to de-convolute the molecular network of host-tumor interactions, and to understand its relationship with treatment effectiveness. They use samples from clinical studies as starting point of their analyses. Investigations are performed according to a “Bedside to Bench and Back” (BB&B) approach, defined as follows: i) hypothesis generation through analysis of samples collected in clinical studies (ex vivo), ii) explanation of the findings through mechanistic investigations (in vitro or in vivo), iii) development of therapeutic strategies acted at interfering/or enhancing the mechanism responsible for immune-resistance/or immune-sensitivity, iv) validation of the hypothesis through clinical/translational trials.